molecule therapeutics, PH-domains, cancer therapy, PLEKHA7 Inhibitors, RAL Inhibitors, Tiam1, CERK inhibitors
http://www.phusistherapeutics.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Saturday
LOAD TIME
0.4 seconds
PHusis Therapeutics
7000 Fan●●●●●●●●ite 2115
Ho●●on , TX, 77030
US
View this contact
PHusis Therapeutics
PHusis Therapeutics
7000 Fan●●●●●●●●ite 2115
Ho●●on , TX, 77030
US
View this contact
PHusis Therapeutics
PHusis Therapeutics
7000 Fan●●●●●●●●ite 2115
Ho●●on , TX, 77030
US
View this contact
BUY YOUR DOMAIN
15
YEARS
1
MONTHS
20
DAYS
NETWORK SOLUTIONS, LLC.
WHOIS : whois.networksolutions.com
REFERRED : http://networksolutions.com
PAGES IN
THIS WEBSITE
2
SSL
EXTERNAL LINKS
0
SITE IP
206.188.193.30
LOAD TIME
0.359 sec
SCORE
6.2
PHusis Therapeutics Delivers Novel PH-Domain Inhibitors for the Treatment of Cancer | phusistherapeutics.com Reviews
https://phusistherapeutics.com
molecule therapeutics, PH-domains, cancer therapy, PLEKHA7 Inhibitors, RAL Inhibitors, Tiam1, CERK inhibitors
phusistherapeutics.com
PHusis Therapeutics | Management Team
http://www.phusistherapeutics.com/Phusis_Therapeutics-Management-Team.html
PDK1 Inhibitor: PHT - 427. D Lynn Kirkpatrick, PHD. Ms Berenjian has over twenty years of experience as controller and financial analyst in small companies in Southern California. She has been involved with companies in all stages of development, and has managed all aspects of accounting for a compliance banking company. She has co-ordinated diligence activities for companies undergoing acquisition, supervising audits and overseeing the transition of accounting policies into new company. Former CEO Merch...
PHusis Therapeutics | About PHusis
http://www.phusistherapeutics.com/Phusis_Therapeutics-About_PHusis.html
PDK1 Inhibitor: PHT - 427. PHusis has built a pipeline of drug leads against some unique cancer targets including PDK1 for mutant NRAS melanoma, and CNKSR1 and PLEK for mutant KRAS in lung and colon cancer, Further refinement and optimizations of these leads will provide agents that will be rapidly advanced through IND enabling studies to clinical trials. PHusis’ first drug candidate, the PDK1 inhibitor PHT-427 has entered IND-enabling preclinical development. Website design by Tribe Design.
TOTAL PAGES IN THIS WEBSITE
2
phusisinc.info
If you are the owner of this domain name, click here to verify. Review our Privacy Policy.
PHusis Therapeutics Delivers Novel PH-Domain Inhibitors for the Treatment of Cancer
PDK1 Inhibitor: PHT - 427. PHusis Delivers Precision Medicines for the Treatment of Cancer. PHusis Therapeutics is developing novel targeted small molecule therapeutics that bind and block the pleckstrin homology (PH)-domain of critical signaling proteins involved in driving cancer cell growth and survival in patients with limited treatment options. 2014 PHusis Therapeutics Inc. 3210 Merryfield Row San Diego, CA 92121 Email us. Website design by Tribe Design.
PHusis Therapeutics Delivers Novel PH-Domain Inhibitors for the Treatment of Cancer
PDK1 Inhibitor: PHT - 427. PHusis Delivers Precision Medicines for the Treatment of Cancer. PHusis Therapeutics is developing novel targeted small molecule therapeutics that bind and block the pleckstrin homology (PH)-domain of critical signaling proteins involved in driving cancer cell growth and survival in patients with limited treatment options. 2014 PHusis Therapeutics Inc. 3210 Merryfield Row San Diego, CA 92121 Email us. Website design by Tribe Design.
Phusis/Letter/Lecture...
MARK E.TEMME IS A LEADING THEORIST ON ASTROPHYSICS. Saturday, August 2, 2008. Infinity/God/Universe/Humanity. "A Lecture" By Mark E. Temme (E PLURIBUS UNUM). Unified Field Theory Paper. Successfully" described a unified field starting with the "first cause", which is. Infinity and time being the two driving spacetime "force dimensions". Phusis/Unified Field Theory and "Infinity Equation". In actuality are a continuum with. The "mind of God" or essence. Abbr version) (O.=E=mc2) by: Mark E. Temme. Thus inf...
PHusis Therapeutics Delivers Novel PH-Domain Inhibitors for the Treatment of Cancer
PDK1 Inhibitor: PHT - 427. PHusis Delivers Precision Medicines for the Treatment of Cancer. PHusis Therapeutics is developing novel targeted small molecule therapeutics that bind and block the pleckstrin homology (PH)-domain of critical signaling proteins involved in driving cancer cell growth and survival in patients with limited treatment options. 2014 PHusis Therapeutics Inc. 3210 Merryfield Row San Diego, CA 92121 Email us. Website design by Tribe Design.
PHusis Therapeutics Delivers Novel PH-Domain Inhibitors for the Treatment of Cancer
PDK1 Inhibitor: PHT - 427. PHusis Delivers Precision Medicines for the Treatment of Cancer. PHusis Therapeutics is developing novel targeted small molecule therapeutics that bind and block the pleckstrin homology (PH)-domain of critical signaling proteins involved in driving cancer cell growth and survival in patients with limited treatment options. 2014 PHusis Therapeutics Inc. 3210 Merryfield Row San Diego, CA 92121 Email us. Website design by Tribe Design.
PHusis Therapeutics Delivers Novel PH-Domain Inhibitors for the Treatment of Cancer
PDK1 Inhibitor: PHT - 427. PHusis Delivers Precision Medicines for the Treatment of Cancer. PHusis Therapeutics is developing novel targeted small molecule therapeutics that bind and block the pleckstrin homology (PH)-domain of critical signaling proteins involved in driving cancer cell growth and survival in patients with limited treatment options. 2014 PHusis Therapeutics Inc. 3210 Merryfield Row San Diego, CA 92121 Email us. Website design by Tribe Design.
PHusis Therapeutics Delivers Novel PH-Domain Inhibitors for the Treatment of Cancer
PDK1 Inhibitor: PHT - 427. PHusis Delivers Precision Medicines for the Treatment of Cancer. PHusis Therapeutics is developing novel targeted small molecule therapeutics that bind and block the pleckstrin homology (PH)-domain of critical signaling proteins involved in driving cancer cell growth and survival in patients with limited treatment options. 2014 PHusis Therapeutics Inc. 3210 Merryfield Row San Diego, CA 92121 Email us. Website design by Tribe Design.
หน้าหลัก
ประก นภ ยรถยนต ช น 1. ประก นภ ยรถยนต ช น 2. ประก นภ ยรถยนต 2Plus. ประก นภ ยรถยนต 3Plus. ความร พ.ร.บ. ความร ประก นภ ยรถยนต. รายช อบร ษ ทประก นภ ย. ล มรห สผ าน? ล มช อผ ใช? ค ณอย ท :. ความร การประก นภ ยรถยนต. ข างสำน กงานขนส ง อ.ก นทรล กษ จ.ศร สะเกษ /โทร 045-810 555 (ว นจ นทร -เสาร ).
ทนายความจังหวัดบุรีรัมย์ ภูษิต ปัญนะทุภา คดีที่ดิน lawyer thailand buriram attorney at law
ต ดต อทนาย โทร 084-7995959 ,089-6649534 Tel,Fax (044) 671626. ทนายภ ษ ต ป ญนะท ภา. ม อถ อ.084-7995959. ประว ต การศ กษาและการอบรม. ปร ญญาตร น ต ศาสตร บ ณฑ ต มหาว ทยาล ยรามคำแหง. ย นด ต อนร บ. การย ดทร พย ส น. การย ดอส งหาร มทร พย ณ ท ทำการ. 1 การย ดอส งหาร มทร พย ณ ท ทำการ (ท ด น, ท ด นพร อมส งปล กสร าง, ห องช ด) ดำเน นการด งน. 12 วางเง นทดรองค าใช จ ายช นบ งค บคด สำนวนละ 2,500 บาท. 13 นำส งเอกสารประกอบการย ดท ด น/ ท ด นพร อมส งปล กสร าง/ ห องช ด ด งต อไปน. 134 แผนท การไปท ต งทร พย ท ย ด.
